■ The efficacy estimates for HbA 1c , SBP and lipids were applied to the first year of treatment. Beyond this period, these risk factors progress according to the panel regressions reported in the UKPDS 68 5 .
■ When blood glucose is not adequately controlled by the combination of metformin (MET) and sulphonylurea (SU), the clinician has to choose between adding a third oral drug or starting insulin therapy.
■ Saxagliptin (SAXA) is a dipeptidyl peptidase 4 inhibitor indicated in adult patients ≥18 years with T2DM to improve glycaemic control in different regimens including, among others, in combination with MET plus a SU when this regimen alone, with diet and exercise, does not provide adequate glycaemic control 3 .
■ Decision-making in health care requires objective consideration of the clinical benefits and economic consequences of the different treatment strategies. The objective of this study was to assess the cost-effectiveness in the Spanish setting of adding SAXA to MET and SU, compared to adding basal insulin (INSbasal). Additionally, the SAXA strategy was compared with a thiazolidinedione (TZD), also added on top of MET and SU. 
no/atc_ddd_index/).
The annual cost of insulin was based on a DDD of 40 IU at baseline, i.e. 0.47 IU/kg (baseline weight = 85.5 kg); however, in the model, insulin dose depended on weight change, hence if 1 kg was gained, the daily dose increased 0.47 IU, and the cost varied accordingly. A reduction of 7.5% was applied to the corresponding drugs according to Royal Decree-Law 8/2010; **Average of glimepiride, glipizide, glibenclamide and gliclazide; ***Insulin glargine was used as INSbasal in the base case scenario, whereas NPH insulin was used in two scenario analyses. Note: costs associated to BMI were included (prescription costs other than antidiabetic drugs) 19 Results ■ The sensitivity analyses confirmed the findings of the base case analysis:
− Deterministic univariate analyses showed that, overall, these results were robust to changes in input parameters identifying the treatment effect on HbA 1c and weight in both arms as the most influential ones.
− At a willingness-to-pay threshold of €30,000 21 per QALY gained, the PSA showed that the SAXA strategy had an 82% probability to be cost-effective in the SNHS compared with the INSbasal strategy (Figure 1 ).
− The SAXA strategy was found either dominant (more effective and less costly) or cost-effective in all the different scenario analyses that were conducted (table 4), being of particular interest when it was assumed that body weight did not affect the quality of life at all or when the intermediateacting insulin (lower price) was used as INSbasal instead of long-acting. 
Additional analysis
■ Compared to TZD add-on to MET plus SU, the triple therapy with SAXA provided a gain of 0.362 QALYs with an increase of €945 in total cost, implying an incremental cost-effectiveness ratio of €2,610 per QALY gained and being cost-effective in the Spanish setting. The conducted sensitivity analyses confirmed the robustness of the results.
■ Saxagliptin was estimated to be a cost-effective option in Spain when a new drug needs to be added in T2DM patients inadequately controlled with metformin and sulphonylurea alone, including when compared with starting a basal insulin regimen in triple therapy.
Perspective, time horizon and sensitivity analyses ■ The perspective of the SNHS was adopted over a lifetime horizon, at a discount rate of 3% (costs and health outcomes) 20 .
■ Deterministic univariate and probabilistic sensitivity analyses (PSA)
were conducted in order to test the impact of uncertainty on the model results. Additionally, scenario analyses intended to assess the variations of key parameters not covered by the previous sensitivity analyses were carried out.
Main analysis
■ SAXA add-on to MET plus SU resulted in a dominant strategy compared to INSbasal add-on to MET plus SU, providing a gain of 0.377 QALYs (95% CI: -0.227 to 0.754) and cost savings of €264 (95% CI: -€1,879 to €2,768) (table 4) .
■ The main explanation of these results is the SAXA tendency to be weight-neutral contrary to weight gain induced by INSbasal. Email contact: Spain.HealthEconomics@astrazeneca.com
